Usun Pharmaceutical

Usun Pharmaceutical is a Taiwan-based clinical-stage biotechnology company specializing in the development of innovative therapeutics through advanced drug delivery and formulation technologies. The company primarily focuses on PEGylation technology and specialized inhalation delivery systems to improve the efficacy, safety, and patient compliance of existing pharmaceutical compounds. Its lead candidate, U0101, is a PEGylated recombinant uricase currently in Phase 2 clinical trials for the treatment of severe gout and hyperuricemia. Usun also maintains a robust pipeline in respiratory medicine, targeting conditions such as pulmonary arterial hypertension. By leveraging its proprietary platforms, Usun Pharmaceutical aims to address significant unmet medical needs in chronic metabolic and respiratory diseases.